Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash & Current Investments (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Cash & Current Investments data on record, last reported at $170.4 million in Q1 2026.

  • On a quarterly basis, Cash & Current Investments rose 82.84% to $170.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $170.4 million, a 82.84% increase, with the full-year FY2025 number at $178.8 million, up 83.27% from a year prior.
  • Cash & Current Investments reached $170.4 million in Q1 2026 per IKT's latest filing, down from $178.8 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for IKT hit a ceiling of $178.8 million in Q4 2025 and a floor of $3.2 million in Q3 2024.
  • A 5-year average of $54.2 million and a median of $26.5 million in 2022 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: tumbled 80.73% in 2024, then soared 2283.81% in 2025.
  • Tracing IKT's Cash & Current Investments over 5 years: stood at $23.1 million in 2022, then crashed by 42.51% to $13.3 million in 2023, then soared by 636.06% to $97.5 million in 2024, then skyrocketed by 83.27% to $178.8 million in 2025, then dropped by 4.7% to $170.4 million in 2026.
  • Business Quant data shows Cash & Current Investments for IKT at $170.4 million in Q1 2026, $178.8 million in Q4 2025, and $77.3 million in Q3 2025.